Clinical trials: Bridging the gap between efficacy and effectiveness

International Review of Psychiatry

Volumn 19, Issue 5, 2007, Pages 531-539

  Depp, Colin ^b   Lebowitz, Barry D ^a  

^a San Diego   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; ETHICS; FUNDING; HUMAN; INFORMATION PROCESSING; METHODOLOGY; OUTCOMES RESEARCH; PATIENT SAFETY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STATISTICAL ANALYSIS; THERAPY; TRAINING;

CLINICAL TRIALS AS TOPIC; CONSUMER PARTICIPATION; FAMILY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; SAFETY; TREATMENT OUTCOME; UNITED STATES;

EID: 34848839198     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701563320     Document Type: Review

References (47)

1. Administration on Aging (2006). Fact sheet on global aging. Available on http://www.aoa.gov/press/fact/fact.asp
2. Bebbington, P. E., Angermeyer, M., Azorin, J. M., Brugha, T., Kilian, R., Johnson, S., et al. (2005). The European schizophrenia cohort (Eurosc): A naturalistic prognostic and economic study. Social Psychiatry And Psychiatric Epidemiology, 40, 707-717.
3. Berwick, D. M. (2002). A user's manual for the iom's 'quality chasm' report. Health Affairs, 21, 80-90.
4. Cassidy, F., Ahearn, E. P., & Carroll, B. J. (2001). Substance abuse in bipolar disorder. Bipolar Disorders, 3, 181-188.
5. Dunn, L. B., Lindamer, L. A., Palmer, B. W., Golshan, S., Schneiderman, L. J., & Jeste, D. V. (2002). Improving understanding of research consent in middle-aged and elderly patients with psychotic disorders. American Journal of Geriatric Psychiatry, 10, 142-150.
6. Glasgow, R. E., Davidson, K. W., Dobkin, P. L., Ockene, J., & Spring, B. (2006). Practical behavioral trials to advance evidence-based behavioral medicine. Annals of Behavioral Medicine, 31, 5-13.
7. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Psychiatry, 6, 278-296.
8. Haro, J. M., & Salvador-Carulla, L. (2006). The SOHO (schizophrenia outpatient health outcome) study: Implications for the treatment of schizophrenia. CNS Drugs, 20, 293-301.
9. Johnson, R. E., & McFarland, B. H. (1996). Lithium use and discontinuation in a health maintenance organization. American Journal of Psychiatry, 153, 993-1000.
10. Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., et al. (2006). Randomized controlled trial of the effect on quality of life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry, 63, 1079-1087.
11. Kaufman, J., & Charney, D. (2000). Comorbidity of mood and anxiety disorders. Depression and Anxiety, 12, 69-76.
12. Kobak, K. A., Engelhardt, N., & Lipsitz, J. D. (2006). Enriched rater training using internet based technologies: A comparison to traditional rater training in a multi-site depression trial. Journal of Psychiatric Research, 40, 192.
13. Kraemer, H. C., & Robinson, T. N. (2005). Are certain multicenter randomized clinical trial structures misleading clinical and policy decisions? Contemporary Clinical Trials, 26, 518.
14. Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002). Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry, 59, 877-883.
15. Lavori, P., Rush, A. J., Wisniewski, S. R., et al. (2001). Strengthening clinical effectiveness trials: Equipoise stratified randomization. Biological Psychiatry, 50, 792-801.
16. Lebowitz, B. D. (1997). The future of clinical research in mental disorders of late life. Schizophrenia Research, 27, 261-267.
17. Lebowitz, B. D. (2004). Clinical trials in late life: New science in old paradigms. Gerontologist, 44, 452-458.
18. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
19. Minkler, M., Blackwell, A. G., Thompson, M., & Tamir, H. (2003). Community-based participatory research: Implications for public health funding. American Journal of Public Health, 93, 1210-1213.
20. Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., et al. (2006). Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210-216.
21. Nierenberg, A. A., Trivedi, M. H., Ritz, L., Burroughs, D., Greist, J., Sackeim, H., et al. (2004). Suicide risk management for the sequenced treatment alternatives to relieve depression study: Applied NIMH guidelines. Journal of Psychiatric Research, 38, 583-589.
22. Norquist, G., Lebowitz, B., & Hyman, S. (1999). Expanding the frontier of treatment research. Prevention and Treatment, 2.
23. Perlick, D. A., Rosenheck, R. A., Kaczynski, R., Swartz, M. S., Canive, J. M., & Lieberman, J. A. (2006). Components and correlates of family burden in schizophrenia. Psychiatric Services, 57, 1117-1125.
24. Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., et al. (2006). Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). American Journal of Psychiatry, 163, 217-224.
25. Piantodosi, S. (2005). Clinical trials: A methodological perspective. New York: Wiley.
26. Rosenbaum, P., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70, 41-55.
27. Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., et al. (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163, 2080-2089.
28. Rubin, D. B. (1976). Inference and missing data. Biometrika, 63, 581-592.
29. Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., et al. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clinical Trials, 25, 119-142.
30. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIS for depression. New England Journal of Medicine, 354, 1231-1242.
31. Sachs, G. S., Thase, M. E., Otto, M. W., Bauer, M., Miklowitz, D., Wisniewski, S. R., et al. (2003). Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry, 53, 1028-1042.
32. Schneider, L., Olin, J., Lyness, S., & Chui, H. (1997). Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of the American Geriatrics Societ, 45, 923-928.
33. Schneider, L. S., Ismail, M. S., Dagerman, K., Davis, S., Olin, J., McManus, D., et al. (2003). Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin, 29, 57-72.
34. Schneider, L. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K. S., Davis, K. L., Davis, S., et al. (2001). National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry, 9, 346-360.
35. Stroup, S., Appelbaum, P., Swartz, M., Patel, M., Davis, S., Jeste, D., et al. (2005). Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research, 80, 1-8.
36. Stroup, T. S., & Appelbaum, P. S. (2006). Evaluation of 'subject advocate' procedures in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study. Schizophrenia Bulletin, 32, 147-152.
37. Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., et al. (2003). The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin, 29, 15-31.
38. Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., et al. (2006). Medication augmentation after the failure of SSRIS for depression. New England Journal of Medicine, 354, 1243-1252.
39. Tunis, S. R., Stryer, D. B., & Clancy, C. M. (2003). Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association, 290, 1624-1632.
40. Warden, D., Rush, A. J., Trivedi, M., Ritz, L., Stegman, D., & Wisniewski, S. R. (2005). Quality improvement methods as applied to a multicenter effectiveness trial - STAR*D. Contemporary Clinical Trials, 26, 95-112.
41. Weissman, M. M., Pilowsky, D. J., Wickramaratne, P. J., Talati, A., Wisniewski, S. R., Fava, M., et al. (2006). Remissions in maternal depression and child psychopathology: A STAR*D-child report. Journal of the American Medical Association, 295, 1389-1398.
42. Wells, K., Miranda, J., Bruce, M. L., Alegria, M., & Wallerstein, N. (2004). Bridging community intervention and mental health services research. American Journal of Psychiatry, 161, 955-963.
43. Wells, K. B. (1999). Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry, 156, 5-10.
44. Wisniewski, S. R., Eng, H., Meloro, L., Gatt, R., Ritz, L., Stegman, D., et al. (2004). Web-based communications and management of a multi-center clinical trial: The sequenced treatment alternatives to relieve depression (STAR*D) project. Clinical Trials, 1, 387-398.
45. Yusuf, S., Collins, R., & Peto, R. (1984). Why do we need some large, simple, randomized trials? Statistics in Medicine, 3(4), 409-422.
46. Zerhouni, E. A. (2006). Clinical research at a crossroads: The NIH roadmap. Journal of Investigational Medicine, May 54(4), 171-173.
47. Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry, 159, 469-473.